IMS Health

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by GreenMountainGate (talk | contribs) at 16:31, 11 October 2016 (added Category:Research and analysis firms). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Ims Health Inc.
Company typePublic
NYSE: IMS
IndustryHealthcare,
Information Services, Technology
Founded1954 as Intercontinental Marketing Services
HeadquartersDanbury, Connecticut
Key people
Ari Bousbib, CEO
ProductsHealthcare Measurement, Analytics & Services, Consulting, Technology Services
Revenue$3.3B[1]
OwnerTPG Capital
CPP Investment Board
Leonard Green & Partners
Number of employees
14,000+[1]
Websitewww.imshealth.com

IMS Health is an American company that provides information, services and technology for the healthcare industry. It is the largest vendor of U.S. physician prescribing data.[2][3][4] IMS Health was founded in 1954 by Bill Frohlich and David Dubow. In 2010, IMS Health was taken private by TPG Capital, CPP Investment Board and Leonard Green & Partners.[5] The company went public on April 4, 2014 and began trading on the NYSE under the symbol IMS.[1][6] Ari Bousbib is IMS Health’s Chairman and CEO. Bousbib, formerly a longtime senior executive at United Technologies Corporation,[7] joined the company in September 2010.[8] IMS Health is headquartered in Danbury, Connecticut.

Business model

IMS Health is best known for its collection of healthcare information spanning sales, de-identified prescription data, medical claims, electronic medical records[9] and social media.[10] IMS Health’s products and services are used by companies to develop commercialization plans[11] and portfolio strategies,[12] to select patient and physician populations for specific therapies, and to measure the effectiveness of pharmaceutical marketing and sales resources.[13] The firm uses its own data to produce syndicated reports such as market forecasts and market intelligence.

History and acquisitions

The original name of the company was Intercontinental Marketing Services, hence the IMS name. IMS Health's corporate headquarters is located in Danbury, Connecticut, United States. The company's chairman and CEO is Ari Bousbib.

  • In 2002, IMS Health acquired Cambridge Pharma Consultancy, a privately held international firm that provides strategic advice to pharmaceutical management.
  • In 2003, acquired Marketing Initiatives, a specialist in healthcare facility profile data, and Data Niche Associates, a provider of rebate validation services for Medicaid and managed care.
  • In 2004, United Research China Shanghai was acquired, providing coverage of China’s consumer health market.
  • In 2005, acquired PharMetrics, a U.S. provider of patient-centric integrated claims data.
  • In 2006, acquired the Life Sciences practice of Strategic Decisions Group, a portfolio strategy consultant to the life sciences industry.
  • In 2007, IMS Health acquired IHS and MedInitiatives, providers of healthcare data management analytics and technology services. That same year, ValueMedics Research was acquired, extending IMS Health’s health economics and outcomes research capabilities.
  • In 2007, ranked in the Businessweek 50. This list represents "best in class" companies from the ten economic sectors that make up the S&P 500.[14]
  • In 2008, named to the World’s Most Admired Companies list by Fortune. The company received the recognition again in 2010.
  • In 2008, acquired RMBC, a provider of national pharmaceutical market intelligence and analytics in Russia.
  • In 2008, acquired the Skura professional services group, based out of Mississauga, Ontario, Canada and specialized in data integration, consulting and services in business intelligence platforms to pharmaceutical and healthcare clients in North America and Europe.
  • In 2009, named to the Dow Jones Sustainability North America Index in recognition of the company’s economic, environmental and social performance among the largest 600 North American companies.
  • In February 2010, IMS Health was taken private by TPG Capital, CPP Investment Board, and Leonard Green & Partners.[15]
  • In 2010, acquired Brogan, Inc., a privately held market research and consulting firm serving the Canada healthcare market.
  • In 2011, expanded its specialty and patient-level data assets in the United States with the acquisition of SDI Health. Also that year, the company acquired Ardentia Ltd in the UK, and Med-Vantage in the United States to build on its payer services in those markets.
  • In 2012, acquired PharmARC Analytic Solutions Pvt. Ltd, a Bangalore-based analytics company.
  • In 2012, acquired DecisionView, a software solutions company that helps life sciences organizations plan and track patient enrollment for clinical trials[16] and TTC,[17] a benchmarking solutions and analytics company that helps clients plan for and negotiate the costs of clinical trials. Also in 2012, the company purchased PharmaDeals Ltd.,[18] a provider of online information about business transactions, licensing, and mergers and acquisitions activity within the pharmaceutical industry.
  • In 2013, acquired several companies to expand its portfolio of SaaS products: Incential Software, a provider of sales performance management technology services; 360 Vantage, which delivers multi-channel CRM software capabilities; Appature, which offers a relationship marketing platform; and Semantelli, a provider of social media analytics for the global healthcare industry.
  • In April 2015, IMS Health completed the purchase of Cegedim's Customer Relationship Management (CRM) software and Strategic Data business for €396 million. Cegedim acquired the software and related business when it purchased Dendrite International in 2007.[19][20][better source needed]
  • In May 2016, the company announced it would merge with Quintiles in an approximate $9 billion deal,[21] in the process creating a new entity called Quintiles IMS. Combined 2015 revenue for the two companies would exceed $7.2 billion and the combined entity is estimated to have a market capitalisation in excess of $17.6 billion.[22][23] IMS Health shareholders will receive 0.384 shares of Quintiles common stock for each share of IMS Health common stock they hold, leaving the split of ownership at 51.4% IMS and 48.6% Quintiles.[24][25] The merger will create one of the largest providers of healthcare data, technology, and services solutions in the world, and is scheduled to close by the second half of 2016.[26]

Controversy

Throughout its history, IMS Health's business of collecting anonymized pharmaceutical sales data has come under scrutiny from both the media and the legal system.[27]

IMS Health v. Ayotte was a free speech case involving IMS Health.[28][29][30]

Sorrell v. IMS Health was a case about physician-data privacy, which went to the U.S. Supreme Court., the High Court ruled in favor of the company.[31][32][33][34]

References

  1. ^ a b c IMS Health Annual Report (10-K), 2014
  2. ^ Steinbrook, R (Jun 29, 2006). "For sale: physicians' prescribing data". The New England Journal of Medicine. 354 (26): 2745–7. doi:10.1056/nejmp068125. PMID 16807410.
  3. ^ Fugh-Berman, A (August 2008). "Prescription tracking and public health". Journal of general internal medicine. 23 (8): 1277–80. doi:10.1007/s11606-008-0630-0. PMID 18473146.
  4. ^ Fugh-Berman, A; Ahari, S (April 2007). "Following the script: how drug reps make friends and influence doctors". PLOS Medicine. 4 (4): e150. doi:10.1371/journal.pmed.0040150. PMID 17455991.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  5. ^ "IMS Health sold to TPG, CPPIB, LG&P"
  6. ^ Picker, Leslie (2014-04-04). "TPG-Backed IMS Health Gains After $1.3 Billion Share Sale". BloombergBusiness.
  7. ^ "CEO's of Tomorrow"
  8. ^ http://www.businessweek.com/magazine/content/10_36/b4193016891032.htm
  9. ^ "What Does IMS Health Do, Anyway?". The Wall Street Journal. 5 November 2009.
  10. ^ Munro, Dan. "New Study Ranks Johnson & Johnson #1 In Pharma For Social Media Engagement". Forbes.
  11. ^ Drive to Develop New Commercial Models.pdf "The Drive to Develop New Commercial Models"
  12. ^ in the News/Documents/Kleinrock, 2011 CA Biomed Industry Report_FINAL.pdf "CA Biomed Industry Report"
  13. ^ Market Maps TL.pdf "Patient Market Maps"
  14. ^ "The Business Week 50" Bloomberg Business Week, Accessed 20 October 2010
  15. ^ "TPG and Pension Plan to Buy IMS Health" New York Times Deal Book, 5 November 2009
  16. ^ "IMS Health to buy clinical trials software company DecisionView"
  17. ^ "IMS Health Acquires TTC, Strengthening Pharma R&D Services Capabilities"
  18. ^ "IMS Health Expands Suite of Syndicated, Web-based Analytics With Acquisition of PharmaDeals Ltd."
  19. ^ http://www.cegedim.com/communique/Cegedim_IMS_Transaction-Closing_01-04-2015_ENG.pdf
  20. ^ fr:Cegedim
  21. ^ Reuters (3 May 2016). "Quintiles is merging with IMS in a deal worth about $9 billion - Fortune". Fortune. {{cite web}}: |author= has generic name (help)
  22. ^ "Quintiles, IMS Health to merge in $9 bln deal". Mail Online. 3 May 2016.
  23. ^ "Quintiles, IMS Health Plan $9B Merger". GEN.
  24. ^ Kristen Hallam; Zachary Tracer (3 May 2016). "IMS Health to Buy Quintiles in $9 Billion Pharma Data Deal". Bloomberg.com.
  25. ^ Erik Holm. "Deals of the Day: IMS Health Merges With Quintiles, Biogen to Spin Off Hemophilia Arm". WSJ.
  26. ^ Reuters Editorial (3 May 2016). "BRIEF-IMS Health and Quintiles to merge". Reuters. {{cite web}}: |author= has generic name (help)
  27. ^ Forbes "Company that Knows What Drugs Everyone Takes Going Public" http://www.forbes.com/sites/adamtanner/2014/01/06/company-that-knows-what-drugs-everyone-takes-going-public/
  28. ^ Baxter, Alexander D. "IMS Health v. Ayotte: A New Direction on Commercial Speech Cases" (PDF). Berkeley Technology Law Journal. 25 (1): 649–670. Retrieved 5 February 2014.
  29. ^ Shapiro, Ilya (28 April 2009). "IMS Health v. Ayotte | Cato Institute". cato.org. Cato Institute. Retrieved 5 February 2014.
  30. ^ Bibet-Kalinyak, Isabelle (2012). "Critical Analysis of Sorrell v. IMS Health, Inc.: Pandora's Box at Best". Food & Drug L.J. 67: 191.
  31. ^ "IMS Health Wins Court Attack on Vermont Marketing Law". Bloomberg. 23 November 2010.
  32. ^ Law360 11 August, 2011. Inside Sorrell V. IMS Health
  33. ^ Adam Liptak for the New York Times. 23 June 2011 Drug Makers Win Two Supreme Court Decisions
  34. ^ Gayland Hethcoat Regulating Pharmaceutical Marketing After Sorrell v. IMS Health Inc. Quinnipiac Health Law Journal. 2012 Vol. 15:187

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=IMS_Health&oldid=743849304"